At a glance
ClinicalIndex Comparison RecordPhase 3Completed
Drug / intervention
torcetrapib/atorvastatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.
In Brief
A Phase 3 clinical trial evaluating torcetrapib/atorvastatin and atorvastatin for Hypercholesterolemia, Familial and Hyperlipidemia. Completed, across 34 sites in 8 countries.
Detailed Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with heterozygous familial hypercholesterolemia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia, Familial, Hyperlipidemia
CountriesCanada, Czechia, Finland, France, Italy, Netherlands, South Africa, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2003
First PostedAug 2005
Study CompletionNov 2006
TodayJul 2026
First PostedAug 29, 2005
Enrollment StartDec 1, 2003
Study CompletionNov 1, 2006
TodayJul 2, 2026
Posted 20.8 years ago
Interventions
torcetrapib/atorvastatindrug
atorvastatindrug